Vmn1r167 Activators
Vmn1r167, identified as a vomeronasal 1 receptor, plays a crucial role in negatively regulating the canonical Wnt signaling pathway. Positioned as a transmembrane protein within the plasma membrane, Vmn1r167 is a key participant in the complex chemosensory system of the vomeronasal organ, where it contributes to the detection and processing of chemical cues. The primary function of Vmn1r167 is to act as a negative regulator of the canonical Wnt signaling pathway, suggesting its involvement in modulating cellular responses to Wnt ligands within the vomeronasal system. The general mechanisms underlying the activation of Vmn1r167 are intricate and involve both direct and indirect pathways. Indirect activation may occur through the modulation of signaling pathways such as the retinoic acid, MAPK, and NF-κB pathways. Retinoic acid, for instance, can influence gene expression by interacting with nuclear receptors, potentially enhancing the expression of Vmn1r167. Similarly, modulators of the MAPK and NF-κB pathways may indirectly activate Vmn1r167 by influencing the expression of transcription factors associated with this receptor. Direct activation involves engagement with specific receptors, such as GPCRs and muscarinic acetylcholine receptors, triggering intracellular signaling cascades that ultimately lead to the up-regulation of Vmn1r167 expression. Additionally, cyclic AMP (cAMP) and its analogs serve as second messengers that directly stimulate Vmn1r167, highlighting the intricate interplay of molecular signals governing the activation of this vomeronasal receptor.
Understanding the complex network of signaling pathways and molecular interactions contributing to Vmn1r167 activation provides valuable insights into the regulatory mechanisms governing chemosensory responses in the vomeronasal organ. The negative modulation of the canonical Wnt signaling pathway by Vmn1r167 suggests its role in fine-tuning cellular responses to specific ligands, thereby shaping the sensitivity of the vomeronasal system to environmental chemical cues. This delicate balance between direct and indirect activation mechanisms underscores the sophisticated nature of Vmn1r167's involvement in the intricate chemosensory processes of the vomeronasal organ.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Indirectly activates Vmn1r167 through the retinoic acid signaling pathway. Retinoic acid influences gene expression via its nuclear receptors, potentially enhancing Vmn1r167 expression. This activation may involve retinoic acid response elements (RAREs) in the regulatory regions of Vmn1r167, leading to an increase in receptor levels. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
Directly stimulates Vmn1r167 by serving as a second messenger. Increased intracellular cAMP levels activate protein kinase A (PKA), which may phosphorylate transcription factors involved in Vmn1r167 expression. This direct activation enhances the receptor's functionality and potentially contributes to downstream signaling in response to specific ligands. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Indirectly activates Vmn1r167 by inhibiting histone deacetylases (HDACs). Trichostatin A alters histone acetylation patterns, promoting an open chromatin state around Vmn1r167 regulatory regions. This epigenetic modification facilitates increased expression of the receptor, contributing to its activation and responsiveness to stimuli in the vomeronasal system. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
Directly stimulates Vmn1r167 by mimicking the effects of cAMP. 8-Br-cAMP is a membrane-permeable analog that elevates intracellular cAMP levels, leading to the activation of PKA and subsequent up-regulation of Vmn1r167. This direct modulation enhances the receptor's expression and functionality, ensuring a heightened responsiveness to chemical signals detected by the vomeronasal system. | ||||||
Carbachol | 51-83-2 | sc-202092 sc-202092A sc-202092C sc-202092D sc-202092B sc-202092E | 1 g 10 g 25 g 50 g 100 g 250 g | $122.00 $281.00 $388.00 $683.00 $1428.00 $3060.00 | 12 | |
Activates Vmn1r167 directly by engaging muscarinic acetylcholine receptors (mAChRs). Carbachol mimics acetylcholine, stimulating mAChRs associated with Vmn1r167. This direct activation triggers intracellular signaling cascades, contributing to the up-regulation of Vmn1r167 expression and promoting cellular responsiveness to relevant chemical cues in the vomeronasal system. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Indirectly influences Vmn1r167 activation by demethylating DNA. 5-Azacytidine is a DNA methyltransferase inhibitor that alters the epigenetic landscape around Vmn1r167 regulatory regions. This modulation leads to increased accessibility and transcriptional activity, indirectly enhancing the expression and activation of Vmn1r167 in response to specific stimuli in the vomeronasal system. | ||||||
Sp-cAMPS | 93602-66-5 | sc-201571 | 1 mg | $97.00 | 3 | |
Directly activates Vmn1r167 by mimicking the effects of cAMP. Sp-cAMPS is a cyclic AMP analog that elevates intracellular cAMP levels, leading to the activation of PKA and subsequent up-regulation of Vmn1r167. This direct modulation enhances the receptor's expression and functionality, ensuring a heightened responsiveness to chemical signals detected by the vomeronasal system. | ||||||
8-pCPT-2′-O-Me-cAMP | 634207-53-7 | sc-257020 | 1 mg | $306.00 | 5 | |
Directly stimulates Vmn1r167 by mimicking the effects of cAMP. 8-pCPT-2'-O-Me-cAMP is a membrane-permeable analog that elevates intracellular cAMP levels, leading to the activation of PKA and subsequent up-regulation of Vmn1r167. This direct modulation enhances the receptor's expression and functionality, ensuring a heightened responsiveness to chemical signals detected by the vomeronasal system. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Activates Vmn1r167 directly by engaging prostaglandin E2 receptors (EP receptors). PGE2 mimics the effects of prostaglandin E2, stimulating EP receptors associated with Vmn1r167. This direct activation triggers intracellular signaling cascades, contributing to the up-regulation of Vmn1r167 expression and promoting cellular responsiveness to relevant chemical cues in the vomeronasal system. | ||||||